Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis
- 1 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (4), 1127-1142
- https://doi.org/10.1093/brain/awaa062
Abstract
Chronic disability in multiple sclerosis is linked to neuroaxonal degeneration. 4-aminopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate ambulatory disability in multiple sclerosis. The presumed mode of action is via blockade of axonal voltage gated potassium channels, thereby enhancing conduction in demyelinated axons. In this study, we provide evidence that in addition to those symptomatic effects, 4-AP can prevent neuroaxonal loss in the CNS. Using in vivo optical coherence tomography imaging, visual function testing and histologic assessment, we observed a reduction in retinal neurodegeneration with 4-AP in models of experimental optic neuritis and optic nerve crush. These effects were not related to an anti-inflammatory mode of action or a direct impact on retinal ganglion cells. Rather, histology and in vitro experiments indicated 4-AP stabilization of myelin and oligodendrocyte precursor cells associated with increased nuclear translocation of the nuclear factor of activated T cells. In experimental optic neuritis, 4-AP potentiated the effects of immunomodulatory treatment with fingolimod. As extended release 4-AP is already licensed for symptomatic multiple sclerosis treatment, we performed a retrospective, multicentre optical coherence tomography study to longitudinally compare retinal neurodegeneration between 52 patients on continuous 4-AP therapy and 51 matched controls. In line with the experimental data, during concurrent 4-AP therapy, degeneration of the macular retinal nerve fibre layer was reduced over 2 years. These results indicate disease-modifying effects of 4-AP beyond symptomatic therapy and provide support for the design of a prospective clinical study using visual function and retinal structure as outcome parameters.Funding Information
- Novartis
- Ilselore-Luckow Foundation
- Doktor Robert Pfleger Foundation
- Forschungskommission of the Heinrich Heine University
- Novartis and Merck
- Heinrich Heine University
- German Federal Ministry of Education and Research (01ZZ1603[A-D], 01ZZ1804[A-H], DIFUTURE)
- Merck Sereno and Sanofi Genzyme
This publication has 44 references indexed in Scilit:
- 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosisExperimental Neurology, 2013
- The OSCAR-IB Consensus Criteria for Retinal OCT Quality AssessmentPLOS ONE, 2012
- Optical Coherence Tomography in Parkinsonian SyndromesPLOS ONE, 2012
- The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis TrialsPLOS ONE, 2011
- Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitisBritish Journal of Pharmacology, 2011
- Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal modelBrain, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulationProceedings of the National Academy of Sciences of the United States of America, 2010
- Aminopyridines Potentiate Synaptic and Neuromuscular Transmission by Targeting the Voltage-activated Calcium Channel β SubunitPublished by Elsevier BV ,2009
- Neuroprotective and Axon Growth-Promoting Effects following Inflammatory Stimulation on Mature Retinal Ganglion Cells in Mice Depend on Ciliary Neurotrophic Factor and Leukemia Inhibitory FactorJournal of Neuroscience, 2009